Description: Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Home Page: guardanthealth.com
GH Technical Analysis
505 Penobscot Drive
Redwood City,
CA
94063
United States
Phone:
855 698 8887
Officers
| Name | Title |
|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director |
| Mr. Michael Bell | Chief Financial Officer |
| Mr. John G. Saia | Chief Legal Officer |
| Dr. Craig Eagle M.D. | Chief Medical Officer |
| Mr. Christopher Freeman | Chief Commercial Officer of Oncology Bus. |
| Mr. Andy Ament | Sr. VP of Operations |
| Darya Chudova | Sr. VP of Technology |
| Mr. Kumud Kalia | Chief Information Officer |
| Ms. Jennifer Higgins | VP of Public Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Providers & Services |
| GIC Sub-Industry: | Health Care Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 25.9492 |
| Price-to-Sales TTM: | 9.8119 |
| IPO Date: | 2018-10-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 1373 |